Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

Revenue declined sharply to $8.7 million in Q2 fiscal year 2025, missing analyst expectations by 34.1% and falling 55.8% compared to the prior year period. Net loss widened to $50.5 million for Q2 ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include next-generation chemistry for ...

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended LDL-cholesterol targets than does usual care alone, data from the VICTORION ...

CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting small interfering RNA (siRNA) targeting Factor XI for ...

Lepodisiran is a small interfering RNA inhibitor designed to inhibit the production of Lp (a).The ALPACA phase 2 trial enrolled 320 participants with Lp (a) levels of 175 nmol/L or higher.

As a small interfering RNA (siRNA) drug, Qfitlia mimics a natural cellular process that regulates gene expression.